E-cadherin expression in endometrial malignancies: Comparison between endometrioid and non-endometrioid carcinomas

Journal of International Medical Research

Volumn 37, Issue 1, 2009, Pages 163-168

  Yalta, Tulin ^a   Atay, L ^b   Atalay, F ^b   Caydere M ^b   Gonultas, M ^b   Ustun, H ^b  

^a Sivas Devlet Hastanesi   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

E cadherin; Endometrioid carcinoma; Non endometrioid carcinoma

Indexed keywords

MONOCLONAL ANTIBODY; UVOMORULIN; CADHERIN;

ARTICLE; CANCER CELL; CARCINOGENESIS; CLEAR CELL CARCINOMA; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; PAPILLARY CARCINOMA; PROTEIN EXPRESSION; CASE CONTROL STUDY; CLASSIFICATION; COMPARATIVE STUDY; ENDOMETRIUM; ENDOMETRIUM TUMOR; METABOLISM; PATHOLOGY;

CADHERINS; CASE-CONTROL STUDIES; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS;

EID: 64149102355     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000903700119     Document Type: Article

References (16)

1. ctn) expression in endometrial cancer and endometrial atypical hyperplasia. J Pathol 2003; 199: 471-478.
2. Matthews RP, Hutchinson-Colas J, Maiman M, et al: Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women. Gynecol Oncol 1997; 65: 206-212.
3. Morrow CP, Bundy BN, Kurman RJ, et al: Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991; 40: 55-65.
4. Holcomb K, Delatorre R, Pedemonte B, et al: E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium. Obstet Gynecol 2002; 100: 1290-1295.
5. Blok P, Craanen ME, Dekker W, et al: Loss of E-cadherin expression in early gastric cancer. Histopathology 1999; 34: 410-415.
6. Sakuragi N, Nishiya M, Ikeda K, et al: Decreased E-cadherin expression in endometrial carcinoma is associated with tumor dedifferentiation and deep myometrial invasion. Gynecol Oncol 1994; 53: 183-189.
7. Fujimoto J, Ichigo S, Hirose R, et al: Suppression of E-cadherin and alpha- and beta-catenin mRNA expression in the metastatic lesions of gynecological cancers. Eur J Gynaecol Oncol 1997; 18: 484-487.
8. Fricke E, Keller G, Becker I, et al: Relationship between E-cadherin gene mutation and p53 gene mutation, p53 accumulation, Bcl-2 expression and Ki-67 staining in diffuse-type gastric carcinoma. Int J Cancer 2003; 104: 60-65.
9. Ascaño JJ, Frierson H Jr, Moskaluk CA, et al: Inactivation of the E-cadherin gene in sporadic diffuse-type gastric cancer. Mod Pathol 2001; 14: 942-949.
10. Motta FJ, Valera ET, Lucio-Eterovic AK, et al: Differential expression of E-cadherin gene in human neuroepithelial tumors. Genet Mol Res 2008; 7: 295-304.
11. Chetty R, Serra S, Asa SL: Loss of membrane localization and aberrant nuclear E-cadherin expression correlates with invasion in pancreatic endocrine tumors. Am J Surg Pathol 2008; 32: 413-419.
12. Shimoyama Y, Nagafuchi A, Fujita S, et al: Cadherin dysfunction in a human cancer cell line: possible involvement of loss of α-catenin expression in reduced cell-cell adhesiveness: Cancer Res 1992; 52: 5770-5774.
13. Goff BA, Kato D, Schmidt RA, et al: Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 1994; 54: 264-268.
14. Hoffman K, Nekhlyudov L, Deligdisch L: Endometrial cancer in elderly women. Gynecol Oncol 1995; 58: 198-201.
15. Furuyama H, Arii S, Mori A, et al: Role of E-cadherin in peritoneal dissemination of the pancreatic cancer cell line, Panc-1, through regulation of cell to cell contact. Cancer Lett 2000; 157: 201-209.
16. Miyamoto S, Baba H, Kuroda S, et al: Changes in E-cadherin associated with cytoplasmic molecules in well and poorly differentiated endometrial cancer. Br J Cancer 2000; 83: 1168-1175.